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Clinical Implications 25 
Mastocytosis is less common among hymenoptera venom allergy patients in the United 26 
States than in Europe. Basal serum tryptase elevations may predict venom 27 
immunotherapy reactions.  28 
 29 
Capsule Summary 30 
Mastocytosis is less common in hymenoptera venom allergy patients in the United 31 
States versus Europe. However, elevated basal serum tryptase may predict venom 32 
immunotherapy reactions, supporting the recommendation to check this in venom 33 
anaphylaxis patients. 34 
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Background: Mastocytosis is a risk factor for hymenoptera venom anaphylaxis (HVA). 56 
Current guidelines recommend measuring tryptase in HVA patients and that those with 57 
mastocytosis pursue lifelong venom immunotherapy (VIT). Available data on HVA and 58 
mastocytosis largely derives from European single-center studies and the prevalence of 59 
HVA with and without mastocytosis in the United States (US) is unknown.  60 
Objective: We sought to determine the prevalence of HVA and mastocytosis in the US 61 
using an insurance claims database and evaluate the impact of mastocytosis on VIT in 62 
HVA patients in a US cohort. 63 
Methods: The IBM Watson Database, consisting of insurance claims from 64 
approximately 27 million US patients in 2018, was queried to identify patients with HVA 65 
and/or mastocytosis. Further, a retrospective study of 161 patients undergoing VIT 66 
between 2015 – 2018 at the University of Michigan (U-M) was conducted.  67 
Results: In the IBM Watson Database, the prevalence of HVA was 167 per 100,000 68 
(0.167%) and the prevalence of mastocytosis 10 per 100,000 (0.010%) overall and 97 69 
per 100,000 (0.097%) among those with HVA. Mastocytosis showed a 9.7-fold increase 70 
among HVA patients versus the general population. In the U-M cohort, 2.6% of VIT 71 
patients had mastocytosis. Tryptase level did not correlate with venom reaction severity 72 
but was higher in patients with systemic VIT reactions.  73 
Conclusions: We observed a lower US HVA prevalence than previously reported. 74 
Mastocytosis was more common in US HVA patients, though at lower rates than 75 
previously reported. In VIT patients there was no correlation between tryptase level and 76 









Hymenoptera venom allergy (HVA) constitutes an IgE-mediated anaphylactic 79 
reaction with a prevalence from 0.5% to 3.3% in the United States (US) and 0.3% to 80 
7.5% in Europe (1, 2). Patients are prescribed epinephrine as a rescue medicine and 81 
may undergo prophylactic venom immunotherapy (VIT); VIT for honeybee, vespids, and 82 
wasp reduces systemic reaction rates from 60% in untreated patients to as low as 0-5% 83 
(3-5). VIT is recommended for patients with anaphylactic venom reactions (3, 5).  84 
Prior work has shown a high prevalence among HVA patients of up to 11.6% (or 85 
11,600 per 100,000) with elevated serum tryptase and up to 5.5% (or 5,500 per 86 
100,000) for clonal mast cell (MC) disease (MCD), including systemic mastocytosis 87 
(SM) (6, 7). Elevated serum tryptase has been linked to severe sting reactions and 88 
reactions during VIT (8, 9). The diagnosis of SM also marks an increased risk for severe 89 
sting reactions and adverse events during VIT (10, 11). Thus, updated AAAAI 90 
guidelines for HVA patients have expanded recommendations for tryptase 91 
measurement in this population (3). However, much of the work supporting high rates of 92 
SM in HVA patients comes from European single-center studies many of which were 93 
also referral centers for mastocytosis and may have carried a selection bias. In addition, 94 
these studies were also performed prior to recognition of hereditary alpha tryptasemia 95 
(6, 7, 12). A recent single-center study of 159 patients from Israel found a lower rate of 96 
tryptase elevation and MC disease when compared to European data (3.8% as 97 
compared to 10-15.9%), suggesting geographic differences in co-occurrence of MCD 98 
and venom allergy may exist. (13). The rate of clonal MCD in the US HVA population 99 








We hypothesized that among HVA and VIT patients, the rate of MCD and 101 
elevated tryptase levels would be lower than European data. We further sought to 102 
evaluate the role of tryptase as a predictive marker in VIT patients given updated 103 









Database  106 
The IBM Watson MarketScan® Research Database was queried for patients with 107 
a diagnosis of HVA (ICD-10 codes T63.44, T63.45, T63.46, Z91.030, Z91.038) and 108 
Mastocytosis (ICD-10 codes D47.01, D47.02, D47.09, C96.21, C94.3). This database 109 
consists of de-identified outpatient, inpatient, and pharmaceutical claims of 110 
approximately 27 million privately insured patients in 2018. Complete claims originate 111 
from over 150 large employer-sponsored health insurance plans with patient coverage 112 
in all 50 states. Real world data from January 1st, 2018 through December 31st, 2018 113 
was obtained for analysis. Eligible patients had 6-12 months of claims data in 2018. 114 
 115 
Allergy Clinic Patient Population 116 
 We conducted a retrospective study of 161 patients with a history of systemic 117 
venom reactions and received venom immunotherapy injections between 2015 and 118 
2018 at the University of Michigan Allergy and Immunology clinic. The University of 119 
Michigan Medical School Institutional Review Board on Human Subjects (IRB) reviewed 120 
and cleared the protocol. Written informed consent was not required because of the 121 
retrospective nature of the study. 122 
 123 
Venom Immunotherapy Protocol 124 
 Patients were selected by the treating physician to undergo VIT based on 125 
available practice parameter guidelines. A history of a venomous sting followed by an 126 








gastrointestinal distress (including nausea, vomiting, or diarrhea), respiratory symptoms 128 
(including cough, wheeze, or dyspnea), loss of consciousness, or documented low 129 
blood pressure was needed to begin venom immunotherapy (3, 5). Patients diagnosed 130 
prior to the 2017 US guidelines may have started VIT based on a systemic cutaneous 131 
reaction according to earlier guidelines and were not excluded from this study (14). 132 
Positive skin or blood specific IgE testing to honeybee, yellow jacket, yellow hornet, 133 
white-faced hornet, or wasp was required. Positive skin testing was defined as a wheal 134 
of 3 mm greater than the negative control on skin prick or intradermal testing; we note 135 
the guideline statements of uncertainty on the intradermal test cutoff, 3 mm over the 136 
negative control was used in this study as it is the consensus among the U-M allergy 137 
group where the study took place (3). Positive blood testing was defined as any serum 138 
IgE level to a venom above the normal range (< 0.35 kU/L) (3). Patients were counseled 139 
on risks and benefits by the treating physician in the course of standard clinical care. 140 
 Venom immunotherapy at the University of Michigan follows US guidelines (3). A 141 
monthly maintenance dose of 1 mL of 100 mcg/mL concentrate for each venom, or 1 142 
mL of 300 mcg/mL for mixed vespid (yellow jacket, yellow hornet, and white-faced 143 
hornet), is used. 0.05 mL of dilutions down to 1:1000 of concentrate, or lower, are used 144 
to build up weekly to maintenance. 145 
 Mastocytosis was diagnosed by the treating physician and the diagnosis was 146 
verified by the study team after reviewing the bone marrow biopsy report and tryptase 147 
values. Mastocytosis was defined according to the 2016 WHO diagnosis and 148 









Data Collection 151 
 A standardized approach was used to collect pre-specified variables from 152 
patients’ charts. Demographic data included age, gender, and race/ethnicity. Medical 153 
history included a history of asthma, atopic sensitization, food allergy, atopic dermatitis, 154 
family history of systemic venom allergy reactions, coronary artery disease, ACE 155 
inhibitor use, and beta blocker use. A positive skin test (a wheal of 3 mm greater than 156 
the negative control) to at least one allergen defined atopy (16). Allergens tested 157 
included trees, grasses, weeds, molds, dust mite, cat, and dog. The original venom 158 
reaction was coded according to the presence or absence of hives/rash, angioedema, 159 
respiratory symptoms (cough, dyspnea, or wheezing), gastrointestinal symptoms 160 
(nausea, vomiting, diarrhea), flushing, loss of consciousness, and low blood pressure. 161 
All reactions were graded I – IV based on a modified Mueller anaphylaxis scale (17).  162 
 Venom skin testing was recorded. For both skin prick and intradermal testing, 163 
wheal and flare in millimeters were recorded. For blood testing, total IgE and individual 164 
venom IgE levels were recorded. Sensitivity to a venom was recorded as a positive skin 165 
or blood test.  166 
 Venom immunotherapy characteristics was recorded, including the time to 167 
maintenance, time on maintenance, total reactions, large local reactions and systemic 168 
reactions (diagnosed by the treating physician).  169 
 Subsequent venom reactions in the field after starting VIT were recorded 170 
identically as the original venom reaction. Tryptase laboratory order status, draw status, 171 








presence of mast cell disease (MCD), subtype, and number of major and minor criteria 173 
for mastocytosis were recorded (18, 19).  174 
 175 
Statistical Analysis 176 
 IBM SPSS version 22 (Armonk, NY) statistical software and GraphPad Prism 177 
(San Diego, CA) were used to perform all statistical analysis. Potentially significant (p < 178 
0.2) associations between patient characteristics and data of interest were initially 179 
evaluated via bivariate correlation and chi-squared analysis. Linear or logistic 180 
regression analysis was then performed as appropriate on all potentially significant 181 
variables to create multivariate associations. A Cochran-Mantel-Haenszel (CMH) test 182 
was used to compare prevalence of mastocytosis in patients with HVA compared to 183 
those with mastocytosis without HVA in the database; this was stratified by adult vs 184 









Database results 187 
The database query included 27,299,530 distinct patients in calendar year 2018. 188 
This revealed a prevalence of 166.8 per 100,000 for HVA overall. Mastocytosis 189 
prevalence was 10.1 per 100,000 overall and 96.7 per 100,000 (or 0.0967%) amongst 190 
HVA patients in 2018; an odds ratio of 9.7 (95% CI 7.2 – 13.1, p <0.0001) was noted 191 
when comparing mastocytosis in patients with HVA compared to those without in 2018 192 
(Figure 1). Among adult (age 18 years and older) patients, the odds ratio was 14.3 (95% 193 
CI 10.5 – 19.6, p < 0.0001). Among pediatric (age < 18 years) patients, there was no 194 
statistical significance (odds ratio 2.4 (95% CI 0.9 – 6.4, p = 0.07). 195 
 196 
Patient Characteristics 197 
 Given the increased prevalence of mastocytosis in real world data, we 198 
investigated the data from our allergy practice in patients with systemic reactions to 199 
hymenoptera, undergoing VIT. University of Michigan is a referral center for MCD. Table 200 
1 displays the demographic and disease-specific characteristics for the patients in the 201 
University of Michigan cohort. The mean age was 47.6 and ranged from 7 – 81 years 202 
old. 41% were female. 24% carried a diagnosis of asthma, 41% had a history of atopic 203 
sensitization to a non-venom allergen. 8% had a family history of venom allergy. 204 
 The average Mueller anaphylaxis grade for the patients’ original reactions was 205 
2.90. This included 34% of patients with a documented low blood pressure and 26% of 206 
patients who lost consciousness. Further, 66% experienced hives or rash, 61% 207 








patients were sensitized to honeybee, 85% to yellow jacket, 68% to yellow hornet, 73% 209 
to white-faced hornet, and 68% to wasp. During venom immunotherapy, 10% 210 
experienced a systemic reaction.  211 
 212 
Impact of VIT on venom allergy course 213 
 VIT was effective in this venom allergy population. Among these 161 patients 214 
who began immunotherapy, 26 (16%) suffered a subsequent venom reaction (table 1). 215 
The mean Mueller grade of these subsequent reactions was 0.96 (table 1), significantly 216 
lower than the mean grade of initial reactions (Fig. 2A). This shows that venom 217 
reactions after VIT were less frequent and less severe than before VIT started. 218 
 We sought to find variables associated with a subsequent venom reaction after 219 
VIT initiation. Using logistic regression, the only significantly correlated variable was a 220 
family history of a systemic venom reaction, with an odds ratio of 8.8 (p = 0.049) (table 221 
2). 4% of patients who did not have subsequent venom reactions had a family history of 222 
a systemic venom reaction, significantly fewer than the 25% rate in patients who did 223 
have a subsequent venom reaction (Fig. 2B).  224 
 225 
Impact of guideline update on practice 226 
 American practice guidelines published in January 2017 recommend measuring 227 
tryptase levels for patients with cardiovascular compromise with venom reactions; these 228 
guidelines suggest consideration of tryptase measurement for all patients with evidence 229 
of venom anaphylaxis (3). We sought to evaluate the impact of these guidelines on 230 







consciousness during the initial venom reaction, the rate of tryptase measurement was 232 
52%, significantly lower than the 81% among patients who lost consciousness during 233 
the initial reaction (Fig. 3A). Before 2017, the rate of tryptase measurement in VIT 234 
patients was 59%; after 2017, the rate was 100%, significantly higher (Fig. 3B).  235 
 236 
Elevated tryptase and clonal MCD in VIT population 237 
 We found 9 patients (5.6%) to have a baseline tryptase level greater than >11.5 238 
ng/mL. Among these, 4 patients underwent bone marrow biopsy and 3 (1.8% of total) 239 
had clonal MCD. Two of these had indolent SM and 1 had monoclonal mast cell 240 
activation syndrome. These patients had significantly higher tryptase levels than 241 
patients who had a tryptase measured but no known MCD (Fig. 4A).  242 
 We sought to evaluate whether tryptase levels correlates with other key features 243 
of HVA. Among patients who had a tryptase level, tryptase did not correlate with the 244 
initial reaction Mueller anaphylaxis grade (Fig. 4B). Elevated tryptase levels appeared in 245 
patients throughout the grading scale. We also sought whether tryptase or other 246 
variables might correlate with a low blood pressure, an indicator of cardiovascular 247 
compromise, during the initial reaction. On logistic regression the only significantly 248 
correlated variables were loss of consciousness, with an odds ratio of 12.9 (p < 0.0001), 249 
and having a tryptase drawn, with an OR of 2.6 (p = 0.039) (table 2). Tryptase level, 250 
whether analyzed as a continuous variable or when broken into discrete groups of 0 – 5 251 
ng/mL, 5 – 11.4 ng/mL, and over 11.4 ng/mL, did not correlate with low blood pressure 252 
during the initial reaction. However, tryptase levels divided according to the same levels 253 








– 11.4 ng/mL had the highest rate of LOC at 50%, significantly higher than the rate of 255 
11% in those with a tryptase greater than 11.4 ng/mL (Fig. 4C).  256 
 Because systemic reactions during VIT are a key adverse effect and worse 257 
reactions have been correlated with higher tryptase levels previously (9), we evaluated 258 
whether this was true in our population. We found a significantly higher mean tryptase 259 
level among patients who had a systemic VIT reaction versus patients who did not (Fig. 260 
4D). Furthermore, to find variables correlated with having a systemic VIT reaction, we 261 
used a multivariate logistic regression that involved all bivariate associations where p 262 
was less than 0.2; the only significantly correlated variable was tryptase level, with an 263 
odds ratio of 1.3 (p = 0.027) per unit increase in tryptase level (table 2). Notably, beta 264 
blocker and ACE-inhibitor use did not correlate with the presence, number, or severity 265 









 VIT is an effective preventative therapy for HVA (3, 5). US guidelines recommend 268 
considering a baseline tryptase level for all HVA patients undergoing VIT and outright 269 
recommend to check in severe venom anaphylaxis (3). Given a high rate of MCD 270 
amongst patients with HVA, up to 7-11%, some authors suggest measuring tryptase 271 
values in all VIT patients (6, 7, 20). SM is associated with failure of VIT, prompting the 272 
noted increased vigilance (10). Bonadonna et al found that among HVA patients, 11.6% 273 
had tryptase levels >11.4 and clonal MCD was detected in 90.9% of patients with 274 
elevated tryptase who underwent further evaluation; at a minimum, 5.5% of the total (a 275 
rate of 5,500 per 100,000) were diagnosed with systemic mastocytosis (7). Further, one 276 
study suggests that patients with severe hypotension and normal basal tryptase values 277 
have rates of MCD up to 75% (21). However, a recent publication from Israel 278 
demonstrated a MCD rate of 3.8% (or 3,800 per 100,000) amongst HVA patients (13), 279 
lower than the figures cited in European data. The rate, to our knowledge, has not been 280 
reported in a US population. In this work, we report a MCD rate among HVA patients of 281 
0.097% in the US population. While this rate cannot be statistically compared directly to 282 
the European or Israeli reports (7, 13) because the current estimate encompasses a 283 
data set of millions versus prior reports involving hundreds patients, this reported rate is 284 
qualitatively lower than prior reports by over an order of magnitude. One explanation for 285 
the higher previously reported rate could be that prior studies occurred mainly within 286 
referral centers for mastocytosis and may have carried a selection bias. 287 
Prior work suggests 56-94% of adults report at least one lifetime hymenoptera 288 








the United States (23) and 0.3-7.5% in Europe (5). We report a one-year prevalence of 290 
0.167% in 2018 in a US cohort, lower than prior reports. Another explanation could be 291 
that our data includes subjects with 6-12 months of data, which might lower the rate of 292 
HVA detected here, as some patients may not have had claims data during this period. 293 
This is a limitation shared with other claims database-based analyses. Furthermore, the 294 
database used in this study does not necessarily include non-privately insured patients, 295 
so the population may not fully represent the entire United States population, thereby 296 
affecting prevalence. The rate of systemic reactions to insects in the US and Europe are 297 
similar, suggesting similar rates of hymenoptera allergy; this could change with 298 
variances in insect species’ distribution. For example, climate change may promote 299 
habitats favorable to invasive insects (24); as the number of insect stings changes by 300 
region the incidence of HVA may also change as recurrent stings have been described 301 
as a risk factor for HVA (23). Another factor that may affect the rate of MCD within the 302 
HVA population is the total MCD burden by population; the prevalence of mastocytosis 303 
in the general population is estimated to be 3 to 13 per 100,000 inhabitants (25). Our 304 
finding of 7.7 per 100,000 falls within the previously reported range. Thus, there might 305 
be a disproportionate change in the incidence of HVA relative to the incidence of mast 306 
related diseases. 307 
Another consideration is the etiology of an elevated tryptase. It has been 308 
estimated that 4-6% of the population has an elevated tryptase (12). Most of these 309 
patients do not have a clonal MCD. Hereditary alpha-tryptasemia (HAT) is a recently 310 
described autosomal dominant trait caused by increased monoallelic α-tryptase copy 311 








HVA patients was performed before the recognition of HAT as a distinct entity, which 313 
may have impacted mast cell disease estimates at that time. It has only been recently 314 
that role of HAT in HVA has been examined. Cohort studies have suggested HAT is 315 
associated with more severe HVA, but may not affect the rate of HVA as the rate of 316 
HAT in some HVA patient cohorts is similar to that of the general population (26, 27). 317 
HAT may be overrepresented in patients with clonal MCD and these may have a 318 
synergistic effect on severity of anaphylaxis (26, 27). If HAT does affect anaphylaxis 319 
severity this may explain why some patients with MCDs have more severe HVA versus 320 
others and why elevated serum tryptase without clonal MCD has been at times 321 
associated with HVA severity. The role of HAT in HVA is an area that requires further 322 
investigation.  323 
Race is increasingly recognized as a factor in many atopic diseases (28). It has 324 
been implicated in not only outcomes disparities, but also in the immunology and 325 
genetics of atopy. The US has a racially and ethnically diverse population. This 326 
heterogeneity of this group could explain differences in MCD and HVA in the US 327 
population compared to Europe. Role of ethnic background in mast cell related disease 328 
and HVA are two areas that require further investigation.           329 
The lower rate of MCD in this study may be due to various factors. The IBM 330 
database relies on the proper coding of the diagnoses of hymenoptera allergy and 331 
mastocytosis. The accuracy of coding can vary with literature suggesting rates of error 332 
from 0-70% (29). This suggests that a significant number of HVA patients are not 333 
screened for MCD. Another limitation is the method diagnosis for HVA, as the initial 334 








hymenoptera sensitization (30), it is possible that patients with non-anaphylactic insect 336 
sting reactions and sensitization to hymenoptera were mislabeled as HVA.    337 
 The role of baseline tryptase in the course of VIT has been explored. Higher 338 
basal tryptase levels have been proposed to predict a high risk of VIT side effects, 339 
particularly during build-up (9). Elevated basal tryptase has also been associated with 340 
severe sting reactions (8, 31, 32), including hypotension and fatality (33). In this work, 341 
the tryptase level was not correlated with the severity of the initial reaction, though this 342 
study involves only those on VIT, which may be a confounding factor. In fact, patients 343 
with the tryptase levels over 11.4 ng/mL had less frequent loss of consciousness than 344 
those with lower tryptase levels (Fig 4C). We do note that in patients with known 345 
mastocytosis, patients with higher basal serum tryptase (e.g. 40 ng/ml or above) are 346 
less likely to have anaphylaxis than those with mild to moderate elevations (34), so 347 
perhaps a similar effect is occurring here in this broader population; more work would 348 
be needed to address this further (11). As our cohort specifically examined VIT patients, 349 
we cannot assess whether tryptase levels correlate with severity of initial reactions 350 
among patients with anaphylactic reactions versus patients with non-anaphylactic 351 
reactions (as that group does not typically undergo VIT). An elevated baseline tryptase 352 
was associated here with systemic reactions to VIT, consistent with prior published 353 
work. 354 
 Allergists may have increased suspicion of underlying mastocytosis when 355 
particular characteristics of the sting reaction are present, such as hypotension without 356 
hives, especially in males (35). This was reflected in our data, as the treating allergist 357 








pressure (Fig. 3A). Furthermore, the guideline changes in the US in 2017 (3) appeared 359 
to impact practice patterns, as all VIT patients started after 2017 had a tryptase level 360 
drawn, compared with before 2017 (Fig. 3B). 361 
Prior authors have suggested no association between anaphylaxis severity and 362 
comorbidities or cardiovascular medications (20, 36). Our data were supportive of this 363 
as well; beta blocker use, ACE-inhibitor use, and cardiovascular disease were not 364 
associated with initial reaction severity, subsequent reaction rate or severity, nor with 365 
the rate of systemic reactions while patients were on VIT.  366 
 Prior literature has suggested an association between HVA and MCD based on 367 
several observations. The prevalence of HVA in SM is higher than the general 368 
population and HVA represents the most common anaphylaxis trigger in adult 369 
mastocytosis patients; there is also more frequent clonal MCD in patients with systemic 370 
HVA than the general population (37). This study supports a relationship between HVA 371 
and mastocytosis with the prevalence of mastocytosis among patients with HVA being 372 
12 fold higher than among the general population. 373 
 In conclusion, mastocytosis may be less common in the US population compared 374 
to European reports with systemic venom reactions, but a strong association remains 375 
between HVA and mastocytosis. In this population of VIT patients, serum tryptase 376 
values do not correlate with severity of venom reactions; indeed, higher levels may 377 
correlate with less frequent loss of consciousness. Baseline serum tryptase elevation 378 
does correlate with more frequent systemic VIT reactions. Beta blocker and ACE-379 
inhibitor use in this population do not correlate with the frequency or severity of venom 380 








help identify MCD patients amongst the HVA population and help predict systemic 382 
reactions to VIT, the MCD rate may be lower in this US population than other 383 
populations. 384 









 The authors acknowledge the patients who contributed data for this work and the 387 
University of Michigan Allergy Clinic staff who perform venom immunotherapy and 388 









1. Bilo MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical 391 
implications. Clin Exp Allergy. 2009;39(10):1467-76. 392 
2. Golden DB, Marsh DG, Kagey-Sobotka A, Freidhoff L, Szklo M, Valentine MD, et al. Epidemiology 393 
of insect venom sensitivity. JAMA. 1989;262(2):240-4. 394 
3. Golden DB, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, et al. Stinging insect 395 
hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol. 2017;118(1):28-54. 396 
4. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial 397 
of immunotherapy in insect hypersensitivity. N Engl J Med. 1978;299(4):157-61. 398 
5. Sturm GJ, Varga EM, Roberts G, Mosbech H, Bilo MB, Akdis CA, et al. EAACI guidelines on 399 
allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2018;73(4):744-64. 400 
6. Bonadonna P, Zanotti R, Pagani M, Caruso B, Perbellini O, Colarossi S, et al. How much specific is 401 
the association between hymenoptera venom allergy and mastocytosis? Allergy. 2009;64(9):1379-82. 402 
7. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, et al. Clonal mast cell 403 
disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase 404 
levels. J Allergy Clin Immunol. 2009;123(3):680-6. 405 
8. Blum S, Gunzinger A, Muller UR, Helbling A. Influence of total and specific IgE, serum tryptase, 406 
and age on severity of allergic reactions to Hymenoptera stings. Allergy. 2011;66(2):222-8. 407 
9. Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, et al. Predictors of side effects during 408 
the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of 409 
baseline serum tryptase. J Allergy Clin Immunol. 2010;126(1):105-11 e5. 410 
10. Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez MI, Sanchez-Munoz L, de Durana MD, 411 
Vega A, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic 412 
mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol. 413 
2008;121(2):519-26. 414 
11. van Anrooij B, van der Veer E, de Monchy JG, van der Heide S, Kluin-Nelemans JC, van Voorst 415 
Vader PC, et al. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in 416 
patients with mastocytosis. J Allergy Clin Immunol. 2013;132(1):125-30. 417 
12. Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y, et al. Elevated basal serum tryptase identifies a 418 
multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564-9. 419 
13. Hershko AY, Shaharabani N, Rosman Y, Meir-Shafrir K, Lachover-Roth I, Cohen Engler A, et al. 420 
Hymenoptera venom allergy in a single-center Israeli cohort: Clinical and laboratory characteristics. J 421 
Allergy Clin Immunol Pract. 2019. 422 
14. Golden DB, Moffitt J, Nicklas RA, Freeman T, Graft DF, Reisman RE, et al. Stinging insect 423 
hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol. 2011;127(4):852-4 e1-23. 424 
15. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel 425 
emerging treatment concepts. Blood. 2017;129(11):1420-7. 426 
16. Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, Tan R, et al. Allergy diagnostic testing: an 427 
updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3 Suppl 3):S1-148. 428 
17. Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res. 1966;3(4):331-3. 429 
18. Volertas S, Schuler CFt, Akin C. New Insights into Clonal Mast Cell Disorders Including 430 
Mastocytosis. Immunol Allergy Clin North Am. 2018;38(3):341-50. 431 
19. Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the 432 
Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer 433 








20. Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over- and underestimated parameters in severe 435 
Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of 436 
urticaria/angioedema. J Allergy Clin Immunol. 2012;130(3):698-704 e1. 437 
21. Zanotti R, Lombardo C, Passalacqua G, Caimmi C, Bonifacio M, De Matteis G, et al. Clonal mast 438 
cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J 439 
Allergy Clin Immunol. 2015;136(1):135-9. 440 
22. Bilo BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin Immunol. 441 
2008;8(4):330-7. 442 
23. Golden DB. Anaphylaxis to insect stings. Immunol Allergy Clin North Am. 2015;35(2):287-302. 443 
24. Vega A, Castro L. Impact of climate change on insect-human interactions. Curr Opin Allergy Clin 444 
Immunol. 2019;19(5):475-81. 445 
25. Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin 446 
North Am. 2014;34(2):283-95. 447 
26. Lyons JJ, Chovanec J, O'Connell MP, Liu Y, Selb J, Zanotti R, et al. Heritable risk for severe 448 
anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1. J 449 
Allergy Clin Immunol. 2020. 450 
27. O'Connell MP, Lyons JJ. Hymenoptera venom-induced anaphylaxis and hereditary alpha-451 
tryptasemia. Curr Opin Allergy Clin Immunol. 2020;20(5):431-7. 452 
28. Castells M. Race and allergy: Are we that different? Ann Allergy Asthma Immunol. 453 
2019;122(5):439-40. 454 
29. O'Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring diagnoses: ICD 455 
code accuracy. Health Serv Res. 2005;40(5 Pt 2):1620-39. 456 
30. Abrams EM, Golden DBK. Approach to Patients with Stinging Insect Allergy. Med Clin North Am. 457 
2020;104(1):129-43. 458 
31. Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, et al. Predictors of severe systemic 459 
anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum 460 
tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on 461 
Insect Venom Hypersensitivity. J Allergy Clin Immunol. 2009;124(5):1047-54. 462 
32. Ludolph-Hauser D, Rueff F, Fries C, Schopf P, Przybilla B. Constitutively raised serum 463 
concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet. 464 
2001;357(9253):361-2. 465 
33. Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and 466 
hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom 467 
immunotherapy. Clin Exp Allergy. 2003;33(9):1216-20. 468 
34. Gulen T, Ljung C, Nilsson G, Akin C. Risk Factor Analysis of Anaphylactic Reactions in Patients 469 
With Systemic Mastocytosis. J Allergy Clin Immunol Pract. 2017;5(5):1248-55. 470 
35. Golden DBK, Carter MC. Insect Sting Anaphylaxis-Or Mastocytosis-Or Something Else? J Allergy 471 
Clin Immunol Pract. 2019;7(4):1117-23. 472 
36. Smith MA, Newton LP, Barcena Blanch MA, Cuervo-Pardo L, Cho L, Newton D, et al. Risk for 473 
Anaphylactic Reaction From Cardiac Catheterization in Patients Receiving beta-Adrenergic Blockers or 474 
Angiotensin-Converting Enzyme-Inhibitors. J Allergy Clin Immunol Pract. 2019. 475 
37. Bonadonna P, Scaffidi L, Boni E. Tryptase values in anaphylaxis and insect allergy. Curr Opin 476 
Allergy Clin Immunol. 2019;19(5):462-7. 477 
 478 








Figure Legends 480 
Figure 1: In 2018, the prevalence of Mastocytosis among patients with hymenoptera 481 
allergy was 9.7 times more than the prevalence among the US general population. 482 
Note: OR = odds ratio, 95% confidence interval listed in parentheses. 483 
 484 
Figure 2: A) Mueller grade of initial reaction (mean 2.90, n=158) compared to Mueller 485 
grade of any subsequent reactions (mean 0.96, n=23). B) The proportion of patients 486 
with a family history of a systemic venom reaction is stratified according to whether the 487 
patient did (4%, n=126) or did not (25%, n=25) have a subsequent venom reaction after 488 
a VIT course. Data represent mean +/- standard error of the mean (SEM). *** p < 0.001, 489 
**** p < 0.0001. 490 
 491 
Figure 3: A) Rate of tryptase measurement stratified by blood pressure drop presence 492 
(52%, n=104) or absence (81%, n=54) at initial reaction. B) Rate of tryptase 493 
measurement rate stratified by date, before 2017 (59%, n=150) or after the start of 2017 494 
(100%, n=11). Data represent mean +/- standard error of the mean (SEM). ** p < 0.01, 495 
*** p < 0.001. 496 
 497 
Figure 4: A) Tryptase level stratified by whether a MCD was present (mean 18.0, n = 3) 498 
or not present (mean 5.0, n = 93). B) Tryptase levels are plotted according to the 499 
Mueller grade of the patient’s initial venom reaction. Mean tryptase: Grade 1 = 7.0 500 
(n=4), Grade 2 = 6.0 (n=15), Grade 3 = 5.2 (n=41), Grade 4 = 5.1 (n=34). C) The 501 








level, with ranges of < 5 ng/mL (34%, n=62), 5 – 11.4 ng/mL (50%, n=24), and > 11.4 503 
ng/mL (11%, n=9). D) Tryptase levels are plotted for patients who did (mean 8.8, n=7) 504 
or did not (mean 5.1, n=73) have systemic reactions during venom immunotherapy 505 










Demographic       
Age (mean years [range]) 47.6 (7-81) 50.8 (18-81) 13.2 (7-17) 
Gender (n [% female]) 66 (41) 65 (44) 1 (7) 
General disease history 
   
History of asthma (n [%]) 39 (24) 35 (24) 4 (29) 
History of other atopic sensitization (n [%]) 66 (41) 63 (43) 3 (21) 
History of atopic dermatitis (n [%]) 15 (9) 10 (7) 5 (36) 
History of food allergy (n [%]) 8 (5) 7 (5) 1 (7) 
Family history of venom allergy (n [%]) 13 (8) 9 (6) 4 (29) 
Beta blocker use (n [%]) 7 (4) 7 (5) 0 (0) 
ACE inhibitor use (n [%]) 9 (6) 9 (6) 0 (0) 
Original venom reaction 
   
Hives or rash (n [%]) 106 (66) 96 (65) 10 (71) 
Angioedema (n [%]) 99 (61) 88 (60) 11 (79) 
Respiratory symptoms (n [%]) 78 (48) 71(48) 8 (57) 
Gastrointestinal symptoms (n [%]) 19 (12) 15 (10) 4 (29) 
Low blood pressure documented (n [%]) 54 (34) 53 (36) 1 (7) 
Loss of consciousness (n [%]) 42 (26) 41 (28) 1 (7) 
Mueller anaphylaxis grade (mean [SD]) 2.90 (0.88) 2.92 (0.90) 2.71 (0.61) 
Venom sensitization 
   
Honeybee (n [%]) 115 (71) 107 (73) 8 (57) 
Yellow jacket (n [%]) 137 (85) 127 (86) 10 (71) 
Yellow hornet (n [%]) 110 (68) 101 (69) 9 (64) 
White-faced hornet (n [%]) 117 (73) 107 (73) 10 (71) 
Wasp (n [%]) 110 (68) 101 (69) 9 (64) 
Venom IT course 
   
Systemic reaction to IT (n [%]) 16 (10) 15 (10) 1 (7) 
Subsequent venom reaction (n [%]) 24 (15) 18 (12) 6 (43) 
Subsequent venom reaction Mueller grade 
(mean [SD]) 
0.96 (0.98) 1.13 (0.97) 0.57 (0.98) 
Tryptase measurement 








Tryptase drawn (n [%]) 99 (61) 91 (62) 8 (57) 
Tryptase value (mean ng/mL [range]) 5.4 (1.5 - 20.9) 
5.5 (1.5 - 
20.9) 
4.4 (2.3 - 8.4) 
MCD (% all patients [% if tryptase measured]) 1.9 (2.6) 2.0 (3.2) 0 (0) 
 509 
Table 1: The baseline characteristics of the patient population are listed in aggregate 510 
and by adults (age 18 and up) and children (age < 18). SD = standard deviation. Mueller 511 
grading delineated in Methods section (17). 512 
 513 





Systemic IT reaction Tryptase 1.3 0.027 
Low blood pressure on first reaction LOC on first reaction 12.9 <0.001 
  Tryptase drawn 2.6 0.039 
Subsequent venom reaction Family history of systemic venom reaction 8.8 0.049 
 514 















OR 9.7 (7.2 – 13.1)
OR 14.3 (10.5 – 19.6)
OR 2.4 (0.9 – 6.4)
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